Suppr超能文献

新型冠状病毒肺炎感染患者的菌血症:病例系列

Bacteremia in Patients Infected With COVID-19: A Case Series.

作者信息

Cusumano Jaclyn A, Dupper Amy C, Malik Yesha, Gavioli Elizabeth M, Banga Jaspreet, Berbel Caban Ana, Nadkarni Devika, Obla Ajay, Vasa Chirag V, Mazo Dana, Altman Deena R

机构信息

Mount Sinai Queens, Queens, New York, USA.

Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, New York, USA.

出版信息

Open Forum Infect Dis. 2020 Nov 12;7(11):ofaa518. doi: 10.1093/ofid/ofaa518. eCollection 2020 Nov.

Abstract

BACKGROUND

Previous viral pandemics have shown that secondary bacterial infections result in higher morbidity and mortality, with being the primary causative pathogen. The impact of secondary bacteremia on mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown.

METHODS

This was a retrospective observational case series of patients with coronavirus disease 2019 (COVID-19) who developed secondary bacteremia across 2 New York City hospitals. The primary end point was to describe 14-day and 30-day hospital mortality rates of patients with COVID-19 and bacteremia. Secondary end points included predictors of 14-day and 30-day hospital mortality in patients with COVID-19 and bacteremia.

RESULTS

A total of 42 patients hospitalized for COVID-19 with secondary bacteremia were identified. Of these patients, 23 (54.8%) and 28 (66.7%) died at 14 days and 30 days, respectively, from their first positive blood culture. Multivariate analysis identified hospital-onset bacteremia (≥4 days from date of admission) and age as significant predictors of 14-day hospital mortality and Pitt bacteremia score as a significant predictor of 30-day hospital mortality (odds ratio [OR], 11.9; 95% CI, 2.03-114.7; = .01; OR, 1.10; 95% CI, 1.03-1.20; = .02; and OR, 1.56; 95% CI, 1.19-2.18; = .003, respectively).

CONCLUSIONS

Bacteremia with is associated with high mortality rates in patients hospitalized with COVID-19. Further investigation is warranted to understand the impact of COVID-19 and secondary bacteremia.

摘要

背景

既往病毒性大流行表明,继发性细菌感染会导致更高的发病率和死亡率,其中[细菌名称]是主要致病病原体。继发性[细菌名称]菌血症对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染患者死亡率的影响尚不清楚。

方法

这是一项针对纽约市两家医院中发生继发性[细菌名称]菌血症的2019冠状病毒病(COVID-19)患者的回顾性观察病例系列研究。主要终点是描述COVID-19合并[细菌名称]菌血症患者的14天和30天医院死亡率。次要终点包括COVID-19合并[细菌名称]菌血症患者14天和30天医院死亡率的预测因素。

结果

共确定了42例因COVID-19住院且发生继发性[细菌名称]菌血症的患者。在这些患者中,自首次血培养阳性起,分别有2于14天和30天死亡,其中23例(54.8%)在14天死亡,28例(66.7%)在30天死亡。多因素分析确定医院获得性菌血症(入院日期起≥4天)和年龄是14天医院死亡率的显著预测因素,而皮特菌血症评分是则是30天医院死亡率的显著预测因素(比值比[OR]分别为11.9;95%置信区间[CI]为2.03 - 114.7;P = 0.01;OR为1.10;95% CI为1.03 - 1.20;P = 0.02;以及OR为1.56;95% CI为1.19 - 2.18;P = 0.003)。

结论

[细菌名称]菌血症与COVID-19住院患者的高死亡率相关。有必要进一步研究以了解COVID-19和继发性[细菌名称]菌血症的影响。

相似文献

1
Bacteremia in Patients Infected With COVID-19: A Case Series.新型冠状病毒肺炎感染患者的菌血症:病例系列
Open Forum Infect Dis. 2020 Nov 12;7(11):ofaa518. doi: 10.1093/ofid/ofaa518. eCollection 2020 Nov.
4
[Impact of Staphylococcus aureus bacteremia in COVID-19 patients].[金黄色葡萄球菌菌血症对新冠肺炎患者的影响]
Rev Esp Quimioter. 2022 Oct;35(5):468-474. doi: 10.37201/req/022.2022. Epub 2022 Jul 22.

引用本文的文献

2
The characteristics of methicillin-resistant co-infection in COVID-19 pneumonia.新型冠状病毒肺炎中耐甲氧西林共感染的特征
Front Cell Infect Microbiol. 2025 May 16;15:1560688. doi: 10.3389/fcimb.2025.1560688. eCollection 2025.
5
Molecular pathogen profiling of COVID-19 coinfections.新冠病毒合并感染的分子病原体分析
BMC Infect Dis. 2024 Dec 19;24(1):1451. doi: 10.1186/s12879-024-10347-7.
10
SARS-CoV-2 infection predisposes patients to coinfection with .SARS-CoV-2 感染使患者易合并感染 。
mBio. 2024 Aug 14;15(8):e0166724. doi: 10.1128/mbio.01667-24. Epub 2024 Jul 22.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验